Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
G Shefer, MM Morales, A Aharon, Y Tabib… - Blood …, 2021 - ashpublications.org
Patients diagnosed with B-cell non-Hodgkin lymphoma (B-NHL), particularly if recently
treated with anti-CD20 antibodies, are at risk of severe COVID-19 disease. Because studies …
treated with anti-CD20 antibodies, are at risk of severe COVID-19 disease. Because studies …
[PDF][PDF] Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
C Perry, E Luttwak, R Balaban, G Shefer, MM Morales… - researchgate.net
Patients diagnosed with B-cell non-Hodgkin lymphoma (B-NHL), particularly if recently
treated with anti-CD20 antibodies, are at risk of severe COVID-19 disease. Because studies …
treated with anti-CD20 antibodies, are at risk of severe COVID-19 disease. Because studies …
[HTML][HTML] Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
C Perry, E Luttwak, R Balaban, G Shefer, MM Morales… - Blood Advances, 2021 - Elsevier
Patients diagnosed with B-cell non-Hodgkin lymphoma (B-NHL), particularly if recently
treated with anti-CD20 antibodies, are at risk of severe COVID-19 disease. Because studies …
treated with anti-CD20 antibodies, are at risk of severe COVID-19 disease. Because studies …
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
C Perry, E Luttwak, R Balaban, G Shefer, MM Morales… - Blood Advances, 2021 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Patients diagnosed with B-cell non-Hodgkin
lymphoma (B-NHL), particularly if recently treated with anti-CD20 antibodies, are at risk of …
lymphoma (B-NHL), particularly if recently treated with anti-CD20 antibodies, are at risk of …
[PDF][PDF] Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
C Perry, E Luttwak, R Balaban, G Shefer, MM Morales… - academia.edu
$0.9 3 103/mL predicted a positive serological response. Median time to achieve positive
serology among anti-CD20 antibody-treated patients was longer in iB-NHL vs aB-NHL. The …
serology among anti-CD20 antibody-treated patients was longer in iB-NHL vs aB-NHL. The …
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
C Perry, E Luttwak, R Balaban, G Shefer… - Blood …, 2021 - cris.bgu.ac.il
Patients diagnosed with B-cell non-Hodgkin lymphoma (B-NHL), particularly if recently
treated with anti-CD20 antibodies, are at risk of severe COVID-19 disease. Because studies …
treated with anti-CD20 antibodies, are at risk of severe COVID-19 disease. Because studies …
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma.
C Perry, E Luttwak, R Balaban, G Shefer… - Blood …, 2021 - europepmc.org
Patients diagnosed with B-cell non-Hodgkin lymphoma (B-NHL), particularly if recently
treated with anti-CD20 antibodies, are at risk of severe COVID-19 disease. Because studies …
treated with anti-CD20 antibodies, are at risk of severe COVID-19 disease. Because studies …
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
C Perry, E Luttwak, R Balaban, G Shefer… - Blood …, 2021 - pubmed.ncbi.nlm.nih.gov
Patients diagnosed with B-cell non-Hodgkin lymphoma (B-NHL), particularly if recently
treated with anti-CD20 antibodies, are at risk of severe COVID-19 disease. Because studies …
treated with anti-CD20 antibodies, are at risk of severe COVID-19 disease. Because studies …
[HTML][HTML] Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
C Perry, E Luttwak, R Balaban, G Shefer… - Blood …, 2021 - ncbi.nlm.nih.gov
Patients diagnosed with B-cell non-Hodgkin lymphoma (B-NHL), particularly if recently
treated with anti-CD20 antibodies, are at risk of severe COVID-19 disease. Because studies …
treated with anti-CD20 antibodies, are at risk of severe COVID-19 disease. Because studies …
[PDF][PDF] Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
C Perry, E Luttwak, R Balaban, G Shefer, MM Morales… - researchgate.net
Patients diagnosed with B-cell non-Hodgkin lymphoma (B-NHL), particularly if recently
treated with anti-CD20 antibodies, are at risk of severe COVID-19 disease. Because studies …
treated with anti-CD20 antibodies, are at risk of severe COVID-19 disease. Because studies …